Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'SERTINDOLE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 70 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Sakai, K; Gao, XM; Hashimoto, T; Tamminga, CA
      Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways

      SYNAPSE
    2. Wilton, LV; Heeley, EL; Pickering, RM; Shakir, SA
      Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine

      JOURNAL OF PSYCHOPHARMACOLOGY
    3. Mir, S; Taylor, D
      Atypical antipsychotics and hyperglycaemia

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    4. Kang, JS; Chen, XL; Rampe, D
      The antipsychotic drugs sertindole and pimozide block erg3, a human brain K+ channel

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    5. Hietala, J; Kuoppamaki, M; Majasuo, H; Palvimaki, EP; Laakso, A; Syvalahti, E
      Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist butnot antagonist binding to 5-HT2c receptors after chronic treatment

      PSYCHOPHARMACOLOGY
    6. Andersen, MP; Pouzet, B
      Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats

      PSYCHOPHARMACOLOGY
    7. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    8. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    9. Sanchez, C; Arnt, J
      In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics

      BEHAVIOURAL PHARMACOLOGY
    10. Carriere, P; Bonhomme, D; Lemperiere, T
      Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)

      EUROPEAN PSYCHIATRY
    11. Frangou, S; Lewis, M
      Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service

      EUROPEAN PSYCHIATRY
    12. Falkai, P; Vogeley, K
      Changes of new atypical substances

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    13. Bogan, AM; Shellhorn, E; Brown, ES; Mcdanald, C; Suppes, T
      Switching outpatients between atypical antipsychotics

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    14. Pezawas, L; Quiner, S; Moertl, D; Tauscher, J; Barnas, C; Kufferle, B; Wolf, R; Kasper, S
      Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    15. Barzega, G; Bogetto, F; Maina, G; Ravizza, L
      Quetiapine in schizophrenic patients: A high- and low-dose double-blind comparison

      EUROPEAN JOURNAL OF PSYCHIATRY
    16. Taylor, DM; McAskill, R
      Atypical antipsychotics and weight gain - a systematic review

      ACTA PSYCHIATRICA SCANDINAVICA
    17. Vanhauwe, JFM; Ercken, M; van de Wiel, D; Jurzak, M; Leysen, JE
      Effects of recent and reference antipsychotic agents at human dopamine D-2and D-3 receptor signaling in Chinese hamster ovary cells

      PSYCHOPHARMACOLOGY
    18. Porter, JH; Varvel, SA; Vann, RE; Philibin, SD; Wise, LE
      Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats

      PSYCHOPHARMACOLOGY
    19. Remington, G; Kapur, S
      Atypical antipsychotics: are some more atypical than others?

      PSYCHOPHARMACOLOGY
    20. Prior, TI; Chue, PS; Tibbo, P; Baker, GB
      Drug metabolism and atypical antipsychotics

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    21. Leucht, S; Pitschel-Walz, G; Abraham, D; Kissling, W
      Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

      SCHIZOPHRENIA RESEARCH
    22. Keck, PE; McElroy, SL; Strakowski, SM
      Schizoaffective disorder: role of atypical antipsychotics

      SCHIZOPHRENIA RESEARCH
    23. Campbell, M; Young, PI; Bateman, DN; Smith, JM; Thomas, SHL
      The use of atypical antipsychotics in the management of schizophrenia

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    24. Harvey, BH; Stein, DJ; Emsley, RA
      The new-generation antipsychotics - Integrating the neuropathology and pharmacology of schizophrenia

      SOUTH AFRICAN MEDICAL JOURNAL
    25. Kane, JM
      Tardive dyskinesia in affective disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    26. Sanchez-Arroyos, R; Guitart, X
      Electrophysiological effects of E-5842, a sigma(1) receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons

      EUROPEAN JOURNAL OF PHARMACOLOGY
    27. Watanabe, R; Hagino, Y
      The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum

      EUROPEAN JOURNAL OF PHARMACOLOGY
    28. Zhang, W; Bymaster, FP
      The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT(2A) and muscarinic receptors

      PSYCHOPHARMACOLOGY
    29. WONG SL; CAO G; MACK R; GRANNEMAN GR
      LACK OF CYP3A INHIBITION EFFECTS OF SERTINDOLE ON TERFENADINE IN HEALTHY-VOLUNTEERS

      International journal of clinical pharmacology and therapeutics
    30. GERACIOTI TD; PARKER S; LOWTHER NB; WORTMAN M; RICHTAND NM
      A CASE OF TREATMENT-REFRACTORY PSYCHOSIS RESPONSIVE TO SERTINDOLE

      Schizophrenia research
    31. GAO XM; SAKAI K; TAMMINGA CA
      CHRONIC OLANZAPINE OR SERTINDOLE TREATMENT RESULTS IN REDUCED ORAL CHEWING MOVEMENTS IN RATS COMPARED TO HALOPERIDOL

      Neuropsychopharmacology
    32. ARNT J
      PHARMACOLOGICAL DIFFERENTIATION OF CLASSICAL AND NOVEL ANTIPSYCHOTICS

      International clinical psychopharmacology
    33. WEHNERT A
      THE EUROPEAN POSTMARKETING OBSERVATIONAL SERDOLECT(R) (EPOS) PROJECT - INCREASING OUR UNDERSTANDING OF SCHIZOPHRENIA THERAPY

      International clinical psychopharmacology
    34. BARNES TRE; MCPHILLIPS MA
      NOVEL ANTIPSYCHOTICS, EXTRAPYRAMIDAL SIDE-EFFECTS AND TARDIVE-DYSKINESIA

      International clinical psychopharmacology
    35. KANE JM
      SERTINDOLE - A REVIEW OF CLINICAL EFFICACY

      International clinical psychopharmacology
    36. HALE AS
      A REVIEW OF THE SAFETY AND TOLERABILITY OF SERTINDOLE

      International clinical psychopharmacology
    37. KASPER S
      HOW MUCH DO NOVEL ANTIPSYCHOTICS BENEFIT THE PATIENTS

      International clinical psychopharmacology
    38. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      ADVERSE-EFFECTS OF THE ATYPICAL ANTIPSYCHOTICS

      The Journal of clinical psychiatry
    39. Daniel, DG; Wozniak, P; Mack, RJ; McCarthy, BG
      Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia

      PSYCHOPHARMACOLOGY BULLETIN
    40. KASPER S; TAUSCHER J; KUFFERLE B; BARNAS C; HESSELMANN B; ASENBAUM S; PODREKA I; BRUCKE T
      SERTINDOLE AND DOPAMINE D-2 RECEPTOR OCCUPANCY IN COMPARISON TO RISPERIDONE, CLOZAPINE AND HALOPERIDOL - A I-123 IBZM SPECT STUDY

      Psychopharmacology
    41. GOUDIE A; TAYLOR A
      COMPARATIVE CHARACTERIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF CLOZAPINE AND OTHER ANTIPSYCHOTICS IN RATS

      Psychopharmacology
    42. WONG SL; LOCKE C; STASER J; GRANNEMAN GR
      LACK OF MULTIPLE DOSING EFFECT OF SERTINDOLE ON THE PHARMACOKINETICS OF ALPRAZOLAM IN HEALTHY-VOLUNTEERS

      Psychopharmacology
    43. RISBY E; DONNIGAN D; NEMEROFF CB
      FORMULARY CONSIDERATIONS FOR TREATING PSYCHIATRIC-DISORDERS - SCHIZOPHRENIA .2.

      Formulary
    44. SCHOOLER NR
      NEW-ANTIPSYCHOTIC MEDICATIONS - STRATEGIES FOR EVALUATION AND SELECTED FINDINGS

      Schizophrenia research
    45. TAMMINGA CA
      THE PROMISE OF NEW DRUGS FOR SCHIZOPHRENIA TREATMENT

      Canadian journal of psychiatry
    46. FARDE L; MACK RJ; NYBERG S; HALLDIN C
      D-2 OCCUPANCY, EXTRAPYRAMIDAL SIDE-EFFECTS AND ANTIPSYCHOTIC DRUG-TREATMENT - A PILOT-STUDY WITH SERTINDOLE IN HEALTHY-SUBJECTS

      International clinical psychopharmacology
    47. CASEY DE
      WILL THE NEW ANTIPSYCHOTICS BRING HOPE OF REDUCING THE RISK OF DEVELOPING EXTRAPYRAMIDAL SYNDROMES AND TARDIVE-DYSKINESIA

      International clinical psychopharmacology
    48. TAMMINGA CA; MACK RJ; GRANNEMAN GR; SILBER CJ; KASHKIN KB
      SERTINDOLE IN THE TREATMENT OF PSYCHOSIS IN SCHIZOPHRENIA - EFFICACY AND SAFETY

      International clinical psychopharmacology
    49. CASEY DE
      THE RELATIONSHIP OF PHARMACOLOGY TO SIDE-EFFECTS

      The Journal of clinical psychiatry
    50. WONG SL; LINNEN P; MACK R; GRANNEMAN GR
      EFFECTS OF FOOD, ANTACID, AND DOSAGE FORM ON THE PHARMACOKINETICS ANDRELATIVE BIOAVAILABILITY OF SERTINDOLE IN HEALTHY-VOLUNTEERS

      Biopharmaceutics & drug disposition
    51. WONG SL; MENACHERRY S; MULFORD D; SCHMITZ PJ; LOCKE C; GRANNEMAN GR
      PHARMACOKINETICS OF SERTINDOLE AND DEHYDROSERTINDOLE IN VOLUNTEERS WITH NORMAL OR IMPAIRED RENAL-FUNCTION

      European Journal of Clinical Pharmacology
    52. CAREY GJ; BERGMAN J
      DISCRIMINATIVE-STIMULUS EFFECTS OF CLOZAPINE IN SQUIRREL-MONKEYS - COMPARISON WITH CONVENTIONAL AND NOVEL ANTIPSYCHOTIC DRUGS

      Psychopharmacology
    53. PILOWSKY LS; OCONNELL P; DAVIES N; BUSATTO GF; COSTA DC; MURRAY RM; ELL PJ; KERWIN RW
      IN-VIVO EFFECTS ON STRIATAL DOPAMINE D-2 RECEPTOR-BINDING BY THE NOVEL ATYPICAL ANTIPSYCHOTIC DRUG SERTINDOLE - A I-123 IBZM SINGLE-PHOTON EMISSION TOMOGRAPHY (SPET) STUDY

      Psychopharmacology
    54. MARDER SR
      PHARMACOLOGICAL TREATMENT STRATEGIES IN ACUTE SCHIZOPHRENIA

      International clinical psychopharmacology
    55. JANICAK PG; DAVIS JM
      ANTIPSYCHOTIC DOSING STRATEGIES IN ACUTE SCHIZOPHRENIA

      International clinical psychopharmacology
    56. TAMMINGA CA; LAHTI AC
      THE NEW-GENERATION OF ANTIPSYCHOTIC-DRUGS

      International clinical psychopharmacology
    57. CASEY DE
      SIDE-EFFECT PROFILES OF NEW ANTIPSYCHOTIC AGENTS

      The Journal of clinical psychiatry
    58. ARNT J
      INHIBITORY EFFECTS ON THE DISCRIMINATIVE STIMULUS PROPERTIES OF D-AMPHETAMINE BY CLASSICAL AND NEWER ANTIPSYCHOTICS DO NOT CORRELATE WITH ANTIPSYCHOTIC ACTIVITY - RELATION TO EFFECTS ON THE REWARD SYSTEM

      Psychopharmacology
    59. SKARSFELDT T
      DIFFERENTIAL EFFECT OF ANTIPSYCHOTICS ON PLACE NAVIGATION OF RATS IN THE MORRIS WATER MAZE - A COMPARATIVE-STUDY BETWEEN NOVEL AND REFERENCE ANTIPSYCHOTICS

      Psychopharmacology
    60. CASEY DE
      BEHAVIORAL-EFFECTS OF SERTINDOLE, RISPERIDONE, CLOZAPINE AND HALOPERIDOL IN CEBUS MONKEYS

      Psychopharmacology
    61. VANKAMMEN DP; MCEVOY JP; TARGUM SD; KARDATZKE D; SEBREE TB; ANDORN A; BAKER RW; SCHOOLER NR; BORISON RL; CASEY D; ERESHEFSKY L; FUNDERBERG L; HAMNER M; KARSON C; MARDER S; MCKINNEY W; SMALL JG; TAMMINGA C; TUASON V; VOLAVKA J; CHUNG L
      A RANDOMIZED, CONTROLLED, DOSE-RANGING TRIAL OF SERTINDOLE IN PATIENTS WITH SCHIZOPHRENIA

      Psychopharmacology
    62. LAHTI AC; TAMMINGA CA
      RECENT DEVELOPMENTS IN THE NEUROPHARMACOLOGY OF SCHIZOPHRENIA

      American journal of health-system pharmacy
    63. COENEN AML; ATES N; SKARSFELDT T; VANLUIJTELAAR ELJM
      EFFECTS OF SERTINDOLE ON SLEEP-WAKE STATES, ELECTROENCEPHALOGRAM, BEHAVIORAL-PATTERNS, AND EPILEPTIC ACTIVITY OF RATS

      Pharmacology, biochemistry and behavior
    64. SUZUKI T; MISAWA M
      SERTINDOLE ANTAGONIZES MORPHINE-INDUCED, COCAINE-INDUCED, AND METHAMPHETAMINE-INDUCED PLACE PREFERENCE IN THE RAT

      Life sciences
    65. DIDRIKSEN M
      EFFECTS OF ANTIPSYCHOTICS ON COGNITIVE-BEHAVIOR IN RATS USING THE DELAYED NON-MATCH TO POSITION PARADIGM

      European journal of pharmacology
    66. SKARSFELDT T
      DIFFERENTIAL-EFFECTS OF REPEATED ADMINISTRATION OF NOVEL ANTIPSYCHOTIC-DRUGS ON THE ACTIVITY OF MIDBRAIN DOPAMINE NEURONS IN THE RAT

      European journal of pharmacology
    67. WEINER I; KIDRON R; TARRASCH R; ARNT J; FELDON J
      THE EFFECTS OF THE NEW ANTIPSYCHOTIC, SERTINDOLE, ON LATENT INHIBITION IN RATS

      Behavioural pharmacology
    68. DOMENEY AM; ARNT J; COSTALL B; NAYLOR RJ; SANCHEZ C; SMITH AG
      EFFECT OF SERTINDOLE ON RAISED MESOLIMBIC DOPAMINERGIC ACTIVITY IN THE RAT

      Drug development research
    69. ANDERSEN K; LILJEFORS T; GUNDERTOFTE K; PERREGAARD J; BOGESO KP
      DEVELOPMENT OF A RECEPTOR-INTERACTION MODEL FOR SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS - PREDICTING SELECTIVITY WITH RESPECT TO DOPAMINE D-2 RECEPTORS

      Journal of medicinal chemistry
    70. SKARSFELDT T
      COMPARISON OF SHORT-TERM ADMINISTRATION OF SERTINDOLE, CLOZAPINE AND HALOPERIDOL ON THE INACTIVATION OF MIDBRAIN DOPAMINE NEURONS IN THE RAT

      European journal of pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/10/19 alle ore 04:52:38